Hepatology International最新文献

{"title":"Combination therapies with immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma with major vascular invasion.","authors":"Tatsuo Kanda, Reina Sasaki-Tanaka, Shuji Terai","doi":"10.1007/s12072-025-10784-9","DOIUrl":"10.1007/s12072-025-10784-9","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"487-489"},"PeriodicalIF":5.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbes associated with functional cure of chronic hepatitis B.","authors":"Takashi Honda, Masatoshi Ishigami, Yoji Ishizu, Norihiro Imai, Takanori Ito, Kenta Yamamoto, Shinya Yokoyama, Hisanori Muto, Yosuke Inukai, Asuka Kato, Asako Murayama, Sachiyo Yoshio, Tetsuya Ishikawa, Mitsuhiro Fujishiro, Hiroki Kawashima, Takanobu Kato","doi":"10.1007/s12072-025-10776-9","DOIUrl":"10.1007/s12072-025-10776-9","url":null,"abstract":"<p><strong>Background and aims: </strong>Hepatitis B virus (HBV) is prevalent worldwide and is difficult to eradicate. Current treatment strategies for chronic hepatitis B ultimately seek to achieve functional cure (FC); however, the factors contributing to FC remain unclear. We aimed to investigate the gut microbiota profiles of patients with chronic hepatitis B who achieved FC.</p><p><strong>Methods: </strong>Among 105 HBeAg-negative patients with chronic hepatitis B, 70 were enrolled, after excluding patients with cirrhosis or hepatocellular carcinoma and those receiving nucleoside analogs. The gut microbiota of patients who achieved FC was assessed and compared with that of patients with high-titer of HBV DNA (HBV DNA ≥ 3.3 log IU/mL) or low-titer of HBV DNA (HBV DNA < 3.3 log IU/mL). Furthermore, we used cell culture-generated HBV (HBVcc) as a model for HBV infection to evaluate the effects of short-chain fatty acids (SCFAs) produced by the identified bacteria.</p><p><strong>Results: </strong>There was no difference in the alpha or beta diversity of the gut microbiota between the FC group and the other groups. However, compared with the other groups, the FC group presented a greater relative abundance of bacteria that produce SCFAs, especially butyrate. In vitro studies demonstrated that 1.0 mM butyrate reduces HBsAg production in HBVcc-infected cells. Furthermore, butyrate administration was most effective at the post-HBV infection stage.</p><p><strong>Conclusions: </strong>Our findings suggest that butyrate-producing bacteria contribute to FC in HBeAg-negative patients with chronic hepatitis B through butyrate-mediated inhibition of HBV production.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"519-528"},"PeriodicalIF":5.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12137416/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, 1990-2021: a multi-model trend analysis and forecasting study.","authors":"Ti Yang, Yang Lei, Leyi Liao, Chen Xie, Xiangyue Mo, Dongqing Cai, Tianzhou Peng, Yuancan Xiao, Changhao Liu, Qingping Li, Jie Zhou, Kai Wang, Chuanjiang Li","doi":"10.1007/s12072-025-10782-x","DOIUrl":"10.1007/s12072-025-10782-x","url":null,"abstract":"<p><strong>Background: </strong>Non-alcoholic fatty liver disease (NAFLD) and its advanced form, non-alcoholic steatohepatitis (NASH), significantly contribute to the increasing incidence of liver cancer due to NASH (NALC), emphasizing the urgent need to address the associated global health burden.</p><p><strong>Methods: </strong>Using the Global Burden of Disease 2021 dataset, we analyzed the incidence, mortality, and disability-adjusted life year (DALY) rates of NALC and NAFLD from 1990 to 2021 across 204 countries. The Joinpoint model, age-period-cohort modeling, decomposition analysis, and frontier analysis were used to assess trends, identify contributing factors, and evaluate health inequities. Projections for future incidence were made using Nordpred and Bayesian age-period-cohort models.</p><p><strong>Results: </strong>The global incidence and mortality rates of NALC have increased significantly. Incidence rose from 14,413.92 cases (95% CI 11,470.95-17,854.24) in 1990 to 42,291.37 (95% CI 34,032.64-51,129.45) in 2021. This trend was particularly evident in low-middle SDI countries, while high SDI countries exhibited declining mortality rates despite rising incidence. Population growth was a primary driver of the increased burden in most regions. Projections suggest that NALC incidence may reach 43,525.53 (95% CI 14,169.28-72,881.77) by 2039, particularly among the elderly, highlighting the serious future risks associated with NALC globally.</p><p><strong>Conclusion: </strong>The findings highlight the growing global burden of NALC driven by NAFLD, especially in low- to middle-income regions. Targeted interventions, alongside a deeper understanding and better resource allocation, are essential to mitigate the rising incidence and address the health disparities associated with this expanding public health challenge.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"619-632"},"PeriodicalIF":5.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment.","authors":"Dawei Ding, Yinan Hu, Gui Jia, Boling Wang, Linhua Zheng, Juan Deng, Ruiqing Sun, Xiufang Wang, Guanya Guo, Lina Cui, Yulong Shang, Ying Han","doi":"10.1007/s12072-024-10743-w","DOIUrl":"10.1007/s12072-024-10743-w","url":null,"abstract":"<p><strong>Background: </strong>Some patients treated with ursodeoxycholic acid (UDCA) or combined fenofibrate had well-controlled biochemical parameters but high liver stiffness, and the prognosis as well as therapeutic options for these patients may be an area worthy of further exploration.</p><p><strong>Aims: </strong>To explore the prognosis and treatment of patients with low-risk and high liver stiffness.</p><p><strong>Methods: </strong>A retrospective study included 424 cases of UDCA monotherapy and 102 cases of combined fenofibrate treatment.</p><p><strong>Results: </strong>The combination of liver stiffness measurement (LSM) and the GLOBE score improved prognostic prediction for patients with UDCA monotherapy (area under the receiver operating characteristic curve [AUC] of 0.868 (0.811-0.925) for the fitted model and 0.834 (0.767-0.900) for the GLOBE score, p = 0.006). Further analyses revealed that LSM had an additive prognostic effect mainly in low-risk patients defined by GLOBE < 0.5 (AUC, 0.777 [0.724-0.825] vs 0.642 [0.583-0.699], p = 0.001). For patients in the low-risk group, the prognosis was worse when LSM > 11 kPa (7/53 [13%] vs 2/227 [1%], p = 0.001). The prognosis was consistent between patients in the \"low-risk and LSM > 11 kPa\" group and the medium-risk group defined by 0.5 < GLOBE < 1.8 (7/53 [13%] vs 22/121 [18%], p = 0.418). In low-risk patients treated with combined fenofibrate therapy, the prognosis was worse when LSM > 11 kPa (3/21 [14%] vs 0/47 [0%], p = 0.022). The prognosis was consistent between patients in the \"low-risk and LSM > 11 kPa\" and the medium-risk groups (3/21 [14%] vs 6/27 [22%], p = 0.353). Antifibrotic drugs failed to reduce the incidence of the primary outcome (5/45 [11%] vs 5/27 [19%], p = 0.598), and delayed the progression of LSM in patients with low-risk and LSM > 11 kPa at 36 months of follow-up (changes in LSM, - 3.31 [- 5.04 to - 1.52] vs - 1.74 [- 2.83 to 1.5], p = 0.046).</p><p><strong>Conclusions: </strong>Patients with GLOBE-defined low-risk and LSM > 11 kPa had a poor prognosis, and antifibrotic therapy may slow the progression of liver stiffness in these patients.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"673-681"},"PeriodicalIF":5.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12137486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study.","authors":"Li Hu, Zhoutian Yang, Zhenyun Yang, Wei Peng, Xiang Tang, Zhiwei Ye, Juncheng Wang, Yizhen Fu, Dandan Hu, Minshan Chen, Yaojun Zhang, Jinbin Chen","doi":"10.1007/s12072-024-10757-4","DOIUrl":"10.1007/s12072-024-10757-4","url":null,"abstract":"<p><strong>Background: </strong>Regorafenib is the recommended second-line therapy for unresectable hepatocellular carcinoma (uHCC). Our study aimed to assess the effect of transition timing to second-line therapy with regorafenib on treatment outcomes in uHCC patients.</p><p><strong>Methods: </strong>In this retrospective study, patients were categorized into prompt transition group (PT group) or delayed transition group (DT group) based on the transition timing to second-line therapy with regorafenib following the first or subsequent occurrence of progressive disease during first-line treatment. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.</p><p><strong>Results: </strong>There were 85 and 122 patients in the PT and DT groups, respectively. The PT group demonstrated significantly better median PFS [4.5 months (95% CI 3.8-6.0) vs. 3.4 months (95% CI 2.8-4.1); HR 0.641; 95% CI 0.478-0.859; p = 0.003], ORR (24.7% vs. 9.8%, p = 0.007), DCR (69.4% vs. 54.9%, p = 0.049), and median OS [17.5 months (95% CI 13.4-not reached) vs. 10.4 months (95% CI 7.9-15.6); HR 0.613; 92% CI 0.432-0.871, p = 0.006] compared to the DT group. Moreover, the overall safety profiles were comparable between groups.</p><p><strong>Conclusion: </strong>The prompt transition to second-line therapy with regorafenib following first-line treatment progression suggests better treatment outcomes and potentially longer survival than in patients who delay the transition to second-line therapy.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"586-595"},"PeriodicalIF":5.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimates of the global prevalence of occult hepatitis B virus infection in population under 18 years old: a systematic review and meta-analysis.","authors":"Yuchen Pan, Zhifang Jia, Yangyu Zhang, Yanhua Wu, Jing Jiang","doi":"10.1007/s12072-025-10816-4","DOIUrl":"10.1007/s12072-025-10816-4","url":null,"abstract":"<p><strong>Objective: </strong>Occult hepatitis B virus infection (OBI) is defined by the presence of hepatitis B virus (HBV) DNA, while HBsAg (Hepatitis B surface antigen) remains undetectable. The infectivity of OBI and its potential ability to contribute to cirrhosis and hepatocellular carcinoma has been reported, with infection in children potentially leading to more severe outcomes. However, the global prevalence and disease burden remain unclear, and this study aimed to assess the prevalence of OBI in population under 18 years old.</p><p><strong>Methods: </strong>We conducted a systematic literature search in PubMed, Embase, Scopus, Cochrane Library, China National Knowledge Infrastructure, and Wanfang Chinese databases for articles evaluating OBI in population under 18 years old. The prevalence of OBI was pooled after quality assessment.</p><p><strong>Results: </strong>A total of 49 studies was included, allowing a meta-analysis of 1,070,526 HBsAg-negative individuals. Data from 28 and 25 studies were extracted for analysis of the high- and low-risk population, respectively. The overall prevalence of OBI in population ≤ 18 years old was 2.1% [95% confidence interval (CI): 0.9%-3.8%] and 9.7% (95% CI: 4.9%-15.8%) in the low- and high-risk population, respectively. In the subgroup analysis of the high-risk population, the OBI prevalence in the African, Eastern Mediterranean, and Western Pacific regions was 21.5% (95% CI: 0.0%-69.9%), 26.8% (95% CI: 13.0%-43.4%), and 4.3% (95% CI: 1.5%-8.2%), respectively. The OBI prevalence was 6.3% (95% CI: 2.7%-11.1%) in children born to mothers infected with HBV, 20.5% (95% CI: 0.0%-66.6%) in population infected with HIV or HCV, and 37.8% (95% CI: 30.8%-45.1%) in population who received blood transfusion. The OBI prevalence was 6.0% (95% CI: 2.4%-11.0%) in participants whose mothers were infected with HBV and vaccinated with hepatitis B vaccine (HepB) and HBIG, 7.1% (95% CI: 0.0%-22.9%) in participants only vaccinated with HepB.</p><p><strong>Conclusion: </strong>The global prevalence of OBI among individuals under 18 years old, particularly in high-risk population, cannot be neglected. Given the stealthy transmission of OBI and its potential for serious clinical outcomes, OBI in population younger than 18 years old should be emphasized as a global health issue.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"493-506"},"PeriodicalIF":5.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on \"Predictive value of soluble PD-1 for HBsAg loss in HBeAg-negative chronic hepatitis B patients: a prospective study\".","authors":"Shimeng Cui, Wei Liu, Chao Wu, Xiaoxi Wang","doi":"10.1007/s12072-025-10844-0","DOIUrl":"https://doi.org/10.1007/s12072-025-10844-0","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144158250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled trial.","authors":"Manoj Kumar, Tushar Madke, Amar Mukund, Yashwant Patidar, Saggere Muralikrishna Shasthry, Chhagan Bihari, Prashant Agarwal, Ankur Jindal, Meenu Bajpai, Rakhi Maiwall, Ashok Choudhary, Vijayraghavan Rajan, Vinod Arora, Harsh Vardhan Thevathia, Babu Lal Meena, Satender Pal Singh, Ashish Maheshwari, Ankit Bhardwaj, Guresh Kumar, Shiv K Sarin","doi":"10.1007/s12072-025-10840-4","DOIUrl":"https://doi.org/10.1007/s12072-025-10840-4","url":null,"abstract":"<p><strong>Background: </strong>The cut-offs of viscoelastic hemostatic assays used for guiding blood products transfusion in patients with cirrhosis undergoing invasive procedures are arbitrary. The aim of this study was to evaluate the efficacy and safety of two different ROTEM thresholds [\"relaxed\" ROTEM thresholds vs. \"conventional\" thresholds used in liver transplantation] for prophylactic blood product transfusion for invasive procedures in advanced cirrhosis patients with impaired traditional coagulation.</p><p><strong>Material and methods: </strong>Patients with advanced cirrhosis scheduled to undergo invasive procedures with high inherent procedure bleeding risk or low inherent procedure bleeding risk along with the presence of any adverse patient specific factors, and abnormalities on conventional coagulation tests requiring correction (any of the following: platelet count < 30 × 10⁹/L, INR > 2.0, and plasma fibrinogen < 100 mg/dL), were randomized to receive correction based on standard ROTEM criteria (n = 519, MELD = 26.5 ± 7.4, CTP score = 12.4 ± 2.3, intrinsic low-risk procedure with any high-risk patient factors = 72.2%, intrinsic high-risk procedure with/without high-risk patient factors = 27.8%) or relaxed ROTEM criteria (n = 524, MELD = 25.6 ± 8.0, CTP score = 12.2 ± 2.7, intrinsic low-risk procedure with any high-risk patient factors = 64.1%, intrinsic high-risk procedure with/without high-risk patient factors = 35.9%). Patients in the standard and relaxed criteria groups received blood components using the following triggers, respectively: Fresh frozen plasma (FFP, 10 ml/kg) when EXTEM-CT > 80 or > 90 s; one pooled of single donor platelet unit or 6 pooled units of random donor platelet when EXTEM-MCF/ FIBTEM-MCF < 35/ ≥ 8 mm or < 30/ ≥ 7 mm; and 5 pooled units of cryoprecipitate if EXTEM-MCF/ FIBTEM-MCF < 35 / < 8 mm or < 30/ < 7 mm. The primary outcome measure was the proportion of patients requiring any blood products transfusion (i.e., FFP /platelets /cryoprecipitate).</p><p><strong>Results: </strong>The proportion of patients transfused any blood product (FFP, platelets or cryoprecipitate) was 287/524 (54.8%) in the relaxed ROTEM group versus 352/519 (67.8%) in the standard ROTEM group (p < 0.001). Procedure-related bleeding and non-bleeding complications and 28-day mortality were similar in both the groups.</p><p><strong>Conclusions: </strong>Relaxation of ROTEM cut-offs leads to lower prophylactic blood products transfusions without increased risk of bleeding in patients with advanced cirrhosis undergoing invasive procedures.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative carbohydrate loading reduces perioperative insulin resistance and hastens functional recovery of remnant liver after living donor hepatectomy: An open-label randomized controlled trial.","authors":"Mahendra Kumar, Nilesh Sadashiv Patil, Nihar Mohapatra, Anil Yadav, Gaurav Sindwani, Udit Dhingra, Sherin Thomas, Viniyendra Pamecha","doi":"10.1007/s12072-025-10831-5","DOIUrl":"10.1007/s12072-025-10831-5","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the effect of preoperative carbohydrate (CHO) loading on perioperative insulin resistance (PIR) and outcomes after live donor hepatectomy. The primary objective of the trial was to compare PIR on postoperative day (POD) 2 between preoperative oral carbohydrate (CHO) loading and overnight fasting groups. The secondary objectives were to compare the functional recovery of the remnant liver, incidence of postoperative nausea and vomiting (PONV) up to 72 h after surgery, inflammatory markers, and length of hospital stay (LOS) between both groups.</p><p><strong>Background: </strong>Preoperative fasting increases perioperative insulin resistance (PIR). Insulin resistance has deleterious effects on liver regeneration following partial hepatectomy.</p><p><strong>Methods: </strong>Single-center, open-label, randomized controlled trial. After exclusion, 70 donors were recruited (35 from each group). Donors in the intervention arm received 50 g of maltodextrin at 10 PM the night before surgery and 25 g of maltodextrin 2 h before anesthesia induction on the day of surgery, whereas those in the control arm followed a minimum of 6 h of overnight fasting. The PIR was assessed using the Homeostatic Model for Assessment of Insulin Resistance (HOMA-IR).</p><p><strong>Results: </strong>Baseline and intraoperative parameters were comparable between the two groups. CHO loading provided better postoperative glycemic control (p < 0.01) and reduced PIR by > 50% (p < 0.01) compared to preoperative fasting. Although postoperative complications, inflammatory markers, and LOS were comparable between the groups, there was a significant attenuation of postoperative nausea (p = 0.01) and vomiting (p = 0.013) with early soft diet tolerance (p = 0.002) in the CHO group. In addition, preoperative carbohydrate loading accelerated functional recovery of the remnant liver, with earlier normalization of serum bilirubin levels (p = 0.002).</p><p><strong>Conclusion: </strong>CHO supplementation is safe and effective in shortening preoperative fasting during donor hepatectomy without significant postoperative risks. It can be considered a standard of care in donor surgery ERAS (Enhanced Recovery After Surgery) protocols for live donor liver transplantations.</p><p><strong>Registration number: </strong>NCT05293444 ( www.</p><p><strong>Clinicaltrials: </strong>gov ).</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel immune-related prognostic models for patients with hepatocellular carcinoma after curative resection.","authors":"Mingnan Cao, Chen Pan, Zhigang Zhao, Sisi Ye, Li Bai, Tingting Zhang","doi":"10.1007/s12072-025-10839-x","DOIUrl":"10.1007/s12072-025-10839-x","url":null,"abstract":"<p><strong>Background: </strong>The patterns of postoperative recurrence vary among hepatocellular carcinoma (HCC) patients and infiltration of immune cells is correlated with patients prognosis. The present study aimed to develop and assess novel nomogram models for postsurgical recurrence and survival in HCC patients by combination of immune cell scores and clinicopathological features.</p><p><strong>Methods: </strong>A total of 233 patients with curative hepatic resection and complete clinicopathologic information were enrolled. The infiltration of CD8 + T lymphocytes, CD15 + neutrophils and CD68 + macrophages in the tumor microenvironment was assessed by immunohistochemistry in tissue microarray. Two prognostic nomogram models for disease-free survival (DFS) and overall survival (OS) were developed and multi-dimensionally evaluated to predict postsurgical HCC outcomes.</p><p><strong>Results: </strong>The DFS nomogram was developed using AFP, GGT, tumor differentiation, Ki-67, and the densities of intratumoral CD15 + neutrophils and CD68 + macrophages. The OS nomogram was established based on gender, AFP, tumor differentiation, number of tumor nodules, microvascular vascular tumor thrombus (MVTT), Ki-67, microvessel density (MVD), the densities of intratumoral CD15 + neutrophils and CD68 + macrophages. The C-indexes for the DFS and OS nomogram were 0.708 (95% CI, 0.675-0.741) and 0.723 (95% CI, 0.688 to 0.758), respectively. The AUC values of the models for 1-, 2- or 5-year DFS were 0.832, 0.807 and 0.783, and for 1-, 2- or 5-year OS were 0.745, 0.794 and 0.842.</p><p><strong>Conclusion: </strong>The present study proposed two nomogram models integrating infiltrating immune cells with clinicopathological risks and showed relatively good predictive performance of recurrence and survival, which may be beneficial to the clinical practice of HCC stratification. Further multicenter studies are needed to assess its general applicability.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}